Treatment and Outcome of In-Stent Restenosis with Drug-Eluting Balloons; A Real-Life Single-Centre Study

Rahid  Ullah; Asim  Ali; Farrukh  Malik; Sara  Ahmed; Syed  Khubaib; Fawad Ali  Siddiqui

doi:10.29054/apmc/2023.1287

Rahid Ullah Interventional Cardiology Fellow, Department of Interventional Cardiology NICVD Karachi, Pakistan
Asim Ali Intervention Cardiology Fellow, Department of Interventional Cardiology, NICVD, Karachi Pakistan
Farrukh Malik Interventional Cardiology Fellow, Department of Interventional Cardiology NICVD Karachi, Pakistan
Sara Ahmed Department of Cardiology, NICVD, Karachi, Pakistan
Syed Khubaib Interventional Cardiology Fellow, Department of Interventional Cardiology NICVD Karachi, Pakistan
Fawad Ali Siddiqui Fellowship in Interventional Cardiology, Senior Registrar Cardiology, Shaheed Mohtarma Benazir Bhutto Medical College and Lyari General Government Hospital, Karachi Pakistan

DOI: https://doi.org/10.29054/apmc/2023.1287

Keywords: DEB in ISR, Ischemic heart disease, Pakistan

Abstract

Background: Potential benefits of drug-eluting balloons (DEBs) in patients suffered from in-stent restenosis was observed in international studies but data is lacking from Pakistan. Objective: Treatment and outcome of In-Stent restenosis with drug-eluting balloons: A real-life hospital-based study. Study Design: Descriptive cross-sectional. Settings: Department of intervention, national institute of cardiovascular diseases, Karachi & other satellite centers, Pakistan. Duration: Between the period of June 2022 and November 2022. Methods: A hospital-based clinical study in which 109 patients were included through a consecutive sampling technique. The eligibility criteria for patients inclusion was, all adult males and females, age ≥18 years, previously treated with a paclitaxel-eluting balloon, and consented to participate. Data were analyzed using SPSS version 26.0 and outcome (MACE, mortality, and TLR) were calculated. Results: The mean age of study participants was 53.27 ± 7.91 years. Majority of the patients were males (n = 72, 66.05%), urban dwellers (58.37%), and married (80.73%). Hypertension was the most common comorbid condition (38.53%). The most common indication was ISR-DES (74.31%, 81). Major adverse cardiovascular events and mortality rate were observed 7.33% and 12.84% vs. 2.75% and 6.42% at 3 and 6 months. Conclusion: Benefits of DEB in ISR have been observed in our study. MACE and mortality were observed less frequent. Patients should be considered for DEB in ISR.